<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107793</url>
  </required_header>
  <id_info>
    <org_study_id>CR108276</org_study_id>
    <secondary_id>2016-002918-43</secondary_id>
    <secondary_id>CNTO1275CRD3005</secondary_id>
    <nct_id>NCT03107793</nct_id>
  </id_info>
  <brief_title>Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab</brief_title>
  <acronym>STARDUST</acronym>
  <official_title>Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of a treat to target strategy coupled&#xD;
      with early endoscopic assessment versus a clinically driven (routine care) approach in&#xD;
      achieving endoscopic response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study investigates benefit of treat to target maintenance treatment strategy versus routine&#xD;
      care to test hypothesis that 'treat to target' ustekinumab (UST) maintenance treatment&#xD;
      strategy coupled with early endoscopic assessment will result in higher endoscopic response&#xD;
      rate after 48 weeks of treatment, compared to pragmatic maintenance treatment strategy. It&#xD;
      consists of screening (5 weeks); treatment period (Week 0 to 48); extension period (Weeks 48&#xD;
      to 104) and safety follow up visit (16 weeks after last dose). Participants will be given an&#xD;
      option to enter ultrasound sub-study to assess intestinal ultrasound (IUS) parameters&#xD;
      indicating transmural changes in response to treatment with UST in participants with Crohn's&#xD;
      disease. Study treatment will be unaffected by participation in sub-study which is optional&#xD;
      for participants of main study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Endoscopic Response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in simple endoscopic score for Crohn's disease (SES-CD) of greater than or equal to (&gt;=) 50 percent (%). SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to any reason, or participants without endoscopic data at Week 48 were analyzed as nonresponders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Response at Week 48 (Premature Drop-outs Excluded)</measure>
    <time_frame>Week 48</time_frame>
    <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in SES-CD score of greater than or equal to (&gt;=) 50%. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to reasons other than lack/loss of efficacy were excluded from the analysis. Participants with missing data were analyzed as non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Response at Week 48 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>Week 48</time_frame>
    <description>Endoscopic response defined as a reduction from baseline in SES-CD score of &gt;= 50%. SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Last observation carried forward: participants who have a missing SES-CD score at Week 48 or who stopped treatment before reaching week 48 had their last SES-CD score carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Week 8, Week 16, Week 48</measure>
    <time_frame>Week 8, 16 and 48</time_frame>
    <description>Clinical response defined as a &gt;=100-point reduction from the baseline Crohn's Disease Activity Index (CDAI) score, or a CDAI score &lt;150. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Remission at Week 8, Week 16, Week 48</measure>
    <time_frame>Week 8, 16 and 48</time_frame>
    <description>Clinical Remission defined as a CDAI score of &lt;150 points. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-remitter.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (&gt;=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Care Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat to Target (T2T) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with &lt;25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with &gt;=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Extension period: From Week 48 to Week 104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score &lt;=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.</description>
    <arm_group_label>All Participants</arm_group_label>
    <arm_group_label>Exploratory Extension period: From Week 48 to Week 104</arm_group_label>
    <arm_group_label>Routine Care Arm</arm_group_label>
    <arm_group_label>Treat to Target (T2T) Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Study:&#xD;
&#xD;
          -  Have active, moderate to severe, ileal and/or colonic Crohn's disease, demonstrated&#xD;
             by: baseline CDAI score of greater than or equal to (&gt;=) 220 and less than equal to&#xD;
             (&lt;=) 450, and endoscopy with evidence of active Crohn's disease (defined as simple&#xD;
             endoscopic score for Crohn's disease [SES-CD] score &gt;=3 excluding the contribution of&#xD;
             the narrowing component score) obtained within the 5 week screening period. A prior&#xD;
             endoscopy may be used only if obtained within 3 months prior to baseline (Week 0), in&#xD;
             which case the prior endoscopy must be centrally read again and SES-CD calculated&#xD;
             based on this second, centralized read-out&#xD;
&#xD;
          -  Has had an inadequate response with, lost response to, was intolerant to, or had&#xD;
             medical contraindications to either conventional therapy, or one previous biologic&#xD;
             therapy approved for the treatment of Crohn's disease in the countries in which the&#xD;
             study is conducted&#xD;
&#xD;
          -  Are eligible according to tuberculosis (TB) infection screening criteria&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) or their legally acceptable representative if&#xD;
             applicable must sign) indicating that he or she understands the purpose of, and&#xD;
             procedures required for, the study and is willing to participate in the study.&#xD;
&#xD;
        Sub-study:&#xD;
&#xD;
          -  Be enrolled into the main study at a participating site&#xD;
&#xD;
          -  Sign a separate ICF indicating that they understand the purpose of and procedures&#xD;
             required for this sub-study and are willing to participate in the sub-study&#xD;
&#xD;
          -  Satisfy all inclusion criteria and none of the exclusion criteria specified in the&#xD;
             main study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Main Study:&#xD;
&#xD;
          -  Has complications of Crohn's disease such as symptomatic strictures or stenoses, short&#xD;
             gut syndrome, or any other manifestation that might be anticipated to require surgery,&#xD;
             could preclude the use of the Crohn's Disease Activity Index (CDAI) to assess response&#xD;
             to therapy, or would possibly confound the ability to assess the effect of treatment&#xD;
             with ustekinumab&#xD;
&#xD;
          -  Currently has or is suspected to have an abscess. Recent cutaneous and perianal&#xD;
             abscesses are not exclusionary if drained and adequately treated at least 3 weeks&#xD;
             prior to baseline, or 8 weeks prior to baseline for intra-abdominal abscesses,&#xD;
             provided there is no anticipated need for any further surgery. Participants with&#xD;
             active fistulas may be included if there is no anticipation of a need for surgery and&#xD;
             there are currently no abscesses identified&#xD;
&#xD;
          -  Has had any kind of bowel resection within 6 months prior to baseline&#xD;
&#xD;
          -  Has a draining (i.e, functioning) stoma or ostomy&#xD;
&#xD;
          -  Has received more than one previous biologic therapy approved for the treatment of&#xD;
             Crohn's disease in the countries in which the study is conducted&#xD;
&#xD;
        Sub-study:&#xD;
&#xD;
          -  Obesity or other characteristics considered likely to preclude intestinal ultrasound&#xD;
             (IUS) visualization of the affected bowel segment&#xD;
&#xD;
          -  Normal bowel wall thickness (BWT) (that is, &lt;=2.0 millimeter [mm] for the terminal&#xD;
             ileum; &lt;=3.0 mm for the colon) for all bowel segments at baseline (Week 0)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Cilag Ltd. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GZA Ziekenhuizen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC MontLegia</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Jan Palfijn Merksem</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EGK s.r.o. - Sanatorium sv. Anny</name>
      <address>
        <city>Prague</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXON Clinical s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIENDO s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicke centrum ISCARE</name>
      <address>
        <city>Praha 9</city>
        <zip>190 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Kommunehospital</name>
      <address>
        <city>Aarhus C.</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abdominalcenter K</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silkeborg Hospital</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Bicetre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital de l Archet</name>
      <address>
        <city>Nice</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon HCL</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-etienne</name>
      <address>
        <city>Saint Priest en jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU-Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Lüneburg</name>
      <address>
        <city>Lueneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Portal10</name>
      <address>
        <city>Muenster</city>
        <zip>48151</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari Ospedale Giovanni XXIII</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Classificato Equiparato Sacro Cuore Don Calabria di Negrar</name>
      <address>
        <city>Negrar (VR)</city>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G.Salvini Ospedale di Rho</name>
      <address>
        <city>RHO</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo - Roma</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli Università Cattolica</name>
      <address>
        <city>Roma</city>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3813 TZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivas Zorggroep, Beatrixziekenhuis</name>
      <address>
        <city>Gorinchem</city>
        <zip>4200 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra, EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário do Algarve</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Central, EPE - Hospital Santo Antonio dos Capuchos</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte, EPE/Hosp. Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Tondela Viseu, EPE</name>
      <address>
        <city>Viseu</city>
        <zip>3504-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP F.D.R. Banska Bystrica</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Department GASTROMART s.r.o.</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center ASSIDUO</name>
      <address>
        <city>Bratislava</city>
        <zip>811 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Bratislava, St. Cyril and Method Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Hepatology Center Nitra, KM Management spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GASTRO I. s.r.o.</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Department ENDOMED, s.r.o.</name>
      <address>
        <city>Vranov nad Toplou</city>
        <zip>093 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Arquitecto Marcide</name>
      <address>
        <city>El Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. de Manises</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. I Politecni La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-11828</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Durham and Darlington NHS Foundation Trust</name>
      <address>
        <city>Darlington</city>
        <zip>DL3 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>E9 7HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's University Hosptial NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03107793/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03107793/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Induction Treatment: Ustekinumab (6 Milligram [mg]/Kilogram [kg])</title>
          <description>Participants were administered with approximately 6 milligram per kilogram (mg/kg) intravenous (IV) injection at Week 0 and 90 mg subcutaneous (SC) injection at Week 8. At Week 16, participants who did not achieved a Crohn's Disease Activity Index (CDAI) improvement (non-responders) of greater than or equal to (&gt;=) 70 points versus Week 0 (CDAI-70), left the study. Participants who achieved CDAI improvement (responders) of at least 70 points versus Week 0 were randomized in open-label maintenance period either with treat to target arm or routine care arm.</description>
        </group>
        <group group_id="P2">
          <title>Treat to Target</title>
          <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
        </group>
        <group group_id="P3">
          <title>Routine Care</title>
          <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="490"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period (16-48 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received A Disallowed Concomitant Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction Treatment: Ustekinumab (6 Milligram [mg]/Kilogram [kg])</title>
          <description>Participants were administered with approximately 6 milligram per kilogram (mg/kg) intravenous (IV) injection at Week 0 and 90 mg subcutaneous (SC) injection at Week 8. At Week 16, participants who did not achieved a Crohn's Disease Activity Index (CDAI) improvement (non-responders) of greater than or equal to (&gt;=) 70 points versus Week 0 (CDAI-70), left the study. Participants who achieved CDAI improvement (responders) of at least 70 points versus Week 0 were randomized in open-label maintenance period either with treat to target arm or routine care arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>BELGIUM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENMARK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITALY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NETHERLANDS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PORTUGAL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLOVAKIA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Endoscopic Response at Week 48</title>
        <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in simple endoscopic score for Crohn's disease (SES-CD) of greater than or equal to (&gt;=) 50 percent (%). SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to any reason, or participants without endoscopic data at Week 48 were analyzed as nonresponders.</description>
        <time_frame>Week 48</time_frame>
        <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Treat to Target</title>
            <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
          </group>
          <group group_id="O2">
            <title>Routine Care</title>
            <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Endoscopic Response at Week 48</title>
          <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in simple endoscopic score for Crohn's disease (SES-CD) of greater than or equal to (&gt;=) 50 percent (%). SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to any reason, or participants without endoscopic data at Week 48 were analyzed as nonresponders.</description>
          <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="31.3" upper_limit="44.5"/>
                    <measurement group_id="O2" value="29.9" lower_limit="23.9" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0933</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Endoscopic Response at Week 48 (Premature Drop-outs Excluded)</title>
        <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in SES-CD score of greater than or equal to (&gt;=) 50%. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to reasons other than lack/loss of efficacy were excluded from the analysis. Participants with missing data were analyzed as non-responder.</description>
        <time_frame>Week 48</time_frame>
        <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized. Here, 'N' (Number of participants analyzed) included all participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treat to Target</title>
            <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
          </group>
          <group group_id="O2">
            <title>Routine Care</title>
            <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Endoscopic Response at Week 48 (Premature Drop-outs Excluded)</title>
          <description>Endoscopic response at Week 48, defined as showing (yes or no) a reduction from baseline in SES-CD score of greater than or equal to (&gt;=) 50%. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Randomized participants who stop treatment before reaching Week 48 due to reasons other than lack/loss of efficacy were excluded from the analysis. Participants with missing data were analyzed as non-responder.</description>
          <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized. Here, 'N' (Number of participants analyzed) included all participants who were evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" lower_limit="35.9" upper_limit="50.3"/>
                    <measurement group_id="O2" value="32.3" lower_limit="25.9" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0362</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Endoscopic Response at Week 48 (Last Observation Carried Forward [LOCF])</title>
        <description>Endoscopic response defined as a reduction from baseline in SES-CD score of &gt;= 50%. SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Last observation carried forward: participants who have a missing SES-CD score at Week 48 or who stopped treatment before reaching week 48 had their last SES-CD score carried forward.</description>
        <time_frame>Week 48</time_frame>
        <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Treat to Target</title>
            <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
          </group>
          <group group_id="O2">
            <title>Routine Care</title>
            <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Endoscopic Response at Week 48 (Last Observation Carried Forward [LOCF])</title>
          <description>Endoscopic response defined as a reduction from baseline in SES-CD score of &gt;= 50%. SES-CD is a validated instrument reflecting an endoscopist global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Last observation carried forward: participants who have a missing SES-CD score at Week 48 or who stopped treatment before reaching week 48 had their last SES-CD score carried forward.</description>
          <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="33.5" upper_limit="46.8"/>
                    <measurement group_id="O2" value="30.8" lower_limit="24.8" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0494</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Week 8, Week 16, Week 48</title>
        <description>Clinical response defined as a &gt;=100-point reduction from the baseline Crohn's Disease Activity Index (CDAI) score, or a CDAI score &lt;150. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-responder.</description>
        <time_frame>Week 8, 16 and 48</time_frame>
        <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Treat to Target</title>
            <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
          </group>
          <group group_id="O2">
            <title>Routine Care</title>
            <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Week 8, Week 16, Week 48</title>
          <description>Clinical response defined as a &gt;=100-point reduction from the baseline Crohn's Disease Activity Index (CDAI) score, or a CDAI score &lt;150. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-responder.</description>
          <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="64.9" upper_limit="77.2"/>
                    <measurement group_id="O2" value="74.7" lower_limit="68.4" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="80.1" upper_limit="89.8"/>
                    <measurement group_id="O2" value="89.6" lower_limit="84.8" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="61.6" upper_limit="74.3"/>
                    <measurement group_id="O2" value="77.8" lower_limit="71.8" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4240</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1802</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0212</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Remission at Week 8, Week 16, Week 48</title>
        <description>Clinical Remission defined as a CDAI score of &lt;150 points. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-remitter.</description>
        <time_frame>Week 8, 16 and 48</time_frame>
        <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Treat to Target</title>
            <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
          </group>
          <group group_id="O2">
            <title>Routine Care</title>
            <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Remission at Week 8, Week 16, Week 48</title>
          <description>Clinical Remission defined as a CDAI score of &lt;150 points. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Participants with missing data were analyzed as non-remitter.</description>
          <population>Randomized analysis set included all participants who received at least 1 dose of study agent and were randomized at Week 16, regardless of study treatment being administered once randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="54.6" upper_limit="67.8"/>
                    <measurement group_id="O2" value="59.7" lower_limit="52.9" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="65.4" upper_limit="77.7"/>
                    <measurement group_id="O2" value="74.2" lower_limit="67.9" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="54.6" upper_limit="67.8"/>
                    <measurement group_id="O2" value="69.7" lower_limit="63.2" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7395</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5603</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0628</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 48</time_frame>
      <desc>Safety analysis set included all participants from full randomized analysis set (FRAS). FRAS included all participants from full analysis set (FAS) that were randomized at Week 16, regardless of study drug being administered. FAS included all enrolled participants who received at least 1 dose of study drug. In Treat-to-target and Routine care arm, adverse events (AE) were counted from Week 0 to Week 48 as planned, that is an overlap exists in AEs reporting among induction and maintenance period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction Period (0-16 Weeks): Ustekinumab (6 Milligram [mg]/Kilogram [kg])</title>
          <description>Participants were administered with approximately 6 milligram per kilogram (mg/kg) intravenous (IV) injection at Week 0 and 90 mg subcutaneous (SC) injection at Week 8. At Week 16, participants who did not achieved a Crohn's Disease Activity Index (CDAI) improvement (non-responders) of greater than or equal to (&gt;=) 70 points versus Week 0 (CDAI-70), left the study. Participants who achieved CDAI improvement (responders) of at least 70 points versus Week 0 were randomized in open-label maintenance period either with treat to target arm or routine care arm.</description>
        </group>
        <group group_id="E2">
          <title>Maintenance Period: Treat to Target (0-48 Weeks)</title>
          <description>Participants with less than (&lt;) 25% improvement in simple endoscopic score for Crohn's disease (SES-CD) score at Week 16 versus baseline received ustekinumab SC dose 8-weekly maintenance treatment while participants with &gt;= 25% improvement in SES-CD score at Week 16 versus baseline received ustekinumab SC dose 12-weekly treatment based on centrally-read ileocolonoscopy findings. From Week 24 for participants assigned to the 8-weekly regimen or from Week 20 for the 12-weekly regimen group ustekinumab maintenance treatment was directed by treat to target assessments based on C-reactive protein (CRP) and CDAI assessments. Participants previously on 12-weekly regimens were adjusted to 8-weekly dosing; those previously on 8-weekly regimens were adjusted to 4-weekly dosing. Participants subsequently failing to meet treatment targets at the next assessment visit 4 weeks after dosing were not able to optimize dosing further and left the study.</description>
        </group>
        <group group_id="E3">
          <title>Maintenance Period: Routine Care (0-48 Weeks)</title>
          <description>Participants received ustekinumab SC dose every 8 weeks or every 12 weeks according to clinical judgment. At Week 16, (ie, 8 weeks after the first SC dose), participants who have not shown adequate response based on the investigator's judgment may receive a second ustekinumab SC dose at that time. Clinical assessments in case of disease flare were performed at investigator's discretion. Participants who lose response during 12-weekly could adjust the dosing to 8-weekly maintenance treatment. Participants previously received 8-weekly ustekinumab treatment were unable to adjust the dose following disease flare and left the study as per investigator's judgment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fistula of Small Intestine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Fluid Collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abscess Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Enteritis Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Infectious Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Large Intestine Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pelvic Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive Ductal Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Temporal Lobe Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="302" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="174" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Microcytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Thyroid Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eye Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pingueculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Skin Tags</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Angular Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anorectal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Aphthous Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Epigastric Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Faeces Discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fistula of Small Intestine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Frequent Bowel Movements</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastric Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastric Polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Sounds Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ileal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oral Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Perianal Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rectal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rectal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tooth Impacted</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Complication Associated with Device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Localised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sense of Oppression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abscess Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Angular Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bacterial Vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Borrelia Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Candida Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chlamydial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fungal Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Genital Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Herpes Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Cutaneous Disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nail Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oral Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Parasitic Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Postoperative Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pulpitis Dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pustule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Streptococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tinea Versicolour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vaginitis Gardnerella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Viral Corneal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Mycotic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Yersinia Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Back Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eye Burns</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eyelid Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Anastomotic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tooth Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Albumin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Bicarbonate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Phosphorus Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Blood Phosphorus Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Clostridium Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Faecal Calprotectin Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastric Ph Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematocrit Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Liver Function Test Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Mean Cell Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Monocyte Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Platelet Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Serum Ferritin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Folate Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Iron Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vitamin B12 Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vitamin D Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Arthritis Enteropathic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Muscle Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tendon Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Tract Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia Benign Monoclonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Melanocytic Naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neoplasm Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Neoplasm Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cluster Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Meralgia Paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>White Matter Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Emotional Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Middle Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Obsessive-Compulsive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Micturition Urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Renal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa Uteri Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Menopausal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Perineal Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Testicular Retraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Varicocele Utero-Ovarian</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nasal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sputum Discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Alopecia Totalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dermal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erythema Nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lichen Planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Fragility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Family Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>DIZZINESS (NO SPECIFITY AVAILABLE)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Peripheral Coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Peripheral Venous Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Phlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>European Medicines Agency (EMEA) Advisor Immunology</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

